• 1
    Burger M, Catto JW, Dalbagni G et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63: 234241
  • 2
    Honma I, Masumori N, Sato E et al. Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology 2004; 64: 744748
  • 3
    Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21: 13151330
  • 4
    Strope SA, Montie JE. The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J Urol 2008; 180: 3137
  • 5
    Schmitz-Drager BJ. Identifying risk factors in patients with non-muscle-invasive bladder cancer: clinical implications. Eur Urol 2011; 60: 721723
  • 6
    Habuchi T. Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model. Future Oncol 2006; 2: 233245
  • 7
    Karagas MR, Tosteson TD, Blum J, Morris JS, Baron JA, Klaue B. Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ Health Perspect 1998; 106 (Suppl. 4): 10471050
  • 8
    Andrew AS, Gui J, Sanderson AC et al. Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet 2009; 125: 527539
  • 9
    Dennis G Jr, Sherman BT, Hosack DA et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 2003; 4: R60.1611
  • 10
    Gui J, Moore JH, Kelsey KT, Marsit CJ, Karagas MR, Andrew AS. A novel survival multifactor dimensionality reduction method for detecting gene-gene interactions with application to bladder cancer prognosis. Hum Genet 2011; 129: 101110
  • 11
    Coffey CS, Hebert PR, Ritchie MD et al. An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation. BMC Bioinformatics 2004; 30: 549559
  • 12
    Coffey CS, Hebert PR, Krumholz HM, Morgan TM, Williams SM, Moore JH. Reporting of model validation procedures in human studies of genetic interactions. Nutrition 2004; 20: 6973
  • 13
    Wang Y, Ichiba M, Iyadomi M, Zhang J, Tomokuni K. Effects of genetic polymorphism of metabolic enzymes, nutrition, and lifestyle factors on DNA adduct formation in lymphocytes. Ind Health 1998; 36: 337346
  • 14
    Itoga S, Nomura F, Makino Y et al. Tandem repeat polymorphism of the CYP2E1 gene: an association study with esophageal cancer and lung cancer. Alcohol Clin Exp Res 2002; 26 (Suppl.):15S19
  • 15
    Park JY, Matsuo K, Suzuki T et al. Impact of smoking on lung cancer risk is stronger in those with the homozygous aldehyde dehydrogenase 2 null allele in a Japanese population. Carcinogenesis 2010; 31: 660665
  • 16
    Langevin F, Crossan GP, Rosado IV, Arends MJ, Patel KJ. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 2011; 475: 5358
  • 17
    McGregor NR. Pueraria lobata (Kudzu root) hangover remedies and acetaldehyde-associated neoplasm risk. Alcohol 2007; 41: 469478
  • 18
    Zhang M, Hu Z, Huang J et al. A 3′-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res 2010; 16: 12361244
  • 19
    Shan ZX, Lin QX, Fu YH et al. Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction. Biochem Biophys Res Commun 2009; 381: 597601
  • 20
    Chang CH, Chang CL, Tsai CW et al. Significant association of an XRCC4 single nucleotide polymorphism with bladder cancer susceptibility in Taiwan. Anticancer Res 2009; 29: 17771782
  • 21
    Figueroa JD, Malats N, Rothman N et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis 2007; 28: 17881793
  • 22
    Mittal RD, Gangwar R, Mandal RK, Srivastava P, Ahirwar DK. Gene variants of XRCC4 and XRCC3 and their association with risk for urothelial bladder cancer. Mol Biol Rep 2011; 39: 16671675
  • 23
    Su D, Ma S, Liu P et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007; 56: 281288
  • 24
    Laucht M, Becker K, El-Faddagh M, Hohm E, Schmidt MH. Association of the DRD4 exon III polymorphism with smoking in fifteen-year-olds: a mediating role for novelty seeking? J Am Acad Child Adolesc Psychiatry 2005; 44: 477484
  • 25
    Das D, Tan X, Easteal S. Effect of model choice in genetic association studies: DRD4 exon III VNTR and cigarette use in young adults. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 346351
  • 26
    Chano T, Ikebuchi K, Ochi Y et al. RB1CC1 activates RB1 pathway and inhibits proliferation and cologenic survival in human cancer. Plos ONE 2010; 5: e11404
  • 27
    Phelps RA, Chidester S, Dehghanizadeh S et al. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell 2009; 137: 623634
  • 28
    Ouelaa-Benslama R, Emami S. Pinworm and TNKS inhibitors, an eccentric duo to derail the oncogenic WNT pathway. Clin Res Hepatol Gastroenterol 2011; 35: 534538
  • 29
    Gelmini S, Quattrone S, Malentacchi F et al. Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience. Clin Chem Lab Med 2007; 45: 862866
  • 30
    Miyamoto H, Yang Z, Chen YT et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 2007; 99: 558568
  • 31
    Pine SR, Mechanic LE, Ambs S et al. Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. J Natl Cancer Inst 2007; 99: 14011409
  • 32
    Chiong E, Kesavan A, Mahendran R et al. NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guerin therapy for bladder cancer. Eur Urol 2011; 59: 430437
  • 33
    Saban MR, O'Donnell MA, Hurst RE et al. Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-alpha. BMC Immunol 2008; 9: 4